Particle.news
Download on the App Store
6 ARTICLES
·
last mo.

JAMA Study Links Abortion Bans to Declines in Evidence‑Based Miscarriage Care

Limits on mifepristone access are steering clinicians away from the most effective miscarriage treatment.

Image
In states that banned abortion at or before 6 weeks of pregnancy, patients were less likely to be given the appropriate medication to facilitate their miscarriages: a two-drug regimen of mifepristone and misoprostol that is identical to the one used in abortions.
A women sits in a health clinic

Overview

  • The national JAMA analysis, published Monday, finds post‑Dobbs trigger bans were followed by a shift away from medication toward waiting without treatment for early miscarriage.
  • In ban states, expectant management rose by 2.8 percentage points and medication use fell by 2.2 percentage points, with no meaningful change in surgical care.
  • For patients who did receive drugs, use of misoprostol alone increased by 13.8 percentage points as the recommended mifepristone‑plus‑misoprostol regimen stalled.
  • More miscarriage cases were first diagnosed in emergency departments in ban states, rising from 21.0% to 26.4% compared with 14.8% to 18.7% elsewhere, signaling delayed access and fewer clinic options.
  • The study reviewed claims for 123,598 commercially insured patients ages 15 to 45 across 14 trigger‑ban states and 17 others from 2018 to September 2024, so effects on Medicaid‑enrolled and uninsured people likely go undercounted.